Home
Networking
Graduate Programs
Education
Research
Research
Grants
Clinical Trials
Cooperative Groups
Cancer Centres and Societies
Cancer Centers
Cancer Societies and Associations
Other Links
Job Postings
Alberta
British Columbia
Ontario
Saskatchewan
Prince Edward Island
New Brunswick
Oncology Groups
COMET
Information
Breast
Latest Oncology Updates
Key Journal Articles
Continuing Medical Education Activities
Lung
Latest Oncology Updates
Key Journal Articles
Multimedia
Continuing Medical Education Activities
GI
Latest Oncology Updates
Key Journal Articles
Multimedia
Continuing Medical Education Activities
GU
Latest Oncology Updates
Guidelines
Key Journal Articles
Continuing Medical Education Activities
Multimedia
Head & Neck
Latest Oncology Updates
Key Journal Articles
Multimedia
Hematology
Latest Oncology Updates
Multimedia
Continuing Medical Education Activities
Palliative Care
Other Tumor Sites
Latest Oncology Updates
Continuing Medical Education Activities
Multimedia
Key Journal Articles
Supportive Care
ACOG July 2011
Hot Spot Newsletter
Key Journal Articles
Patient Care
Guidelines
Teaching Cases
Conferences
Canadian Achievements in Cancer Research
Canadian Contributions to Cancer Clinical Trials - Panel Discussion
Best of Oncology 2012
Oncology Conferences
CME Events
Events Calendar
ASCO 2012
Breast Cancer Updates - ASCO 2012
GI Cancer Updates - ASCO 2012
GU Cancer Updates - ASCO 2012
Head and Neck Cancer Updates - ASCO 2012
Hematology Cancer Updates - ASCO 2012
Lung Cancer Updates - ASCO 2012
Residents
MOBS 2012
NOYCIA Awards
Fellowships
Canada
United States
International
Multimedia
Breast Cancer Multimedia
Lung Cancer Multimedia
GI Cancer Multimedia
Videos
Presentations
GU Cancer Multimedia
Video
Presentations
Head & Neck Cancer Multimedia
Melanoma
Hematology Multimedia
Other Tumor Sites/General Topics Multimedia
Slide Kits & Presentations
Contact
Site Map
In The Clinic
Treatment Summaries / Practice Guidelines
Decision Aids
Drug Information
Clinical Trials
rss-feed
Twitter
linkedin
facebook
Log In
Home
>
Information
>
Breast
>
Key Journal Articles
>
Key Breast Journal Articles - Targeted Agents
Key Breast Journal Articles - Targeted Agents
Published: Fri Apr 29, 2011 Updated:Thu Sep 29, 2011
Treatment of Metastatic ErbB2-positive Breast Cancer: Options After Progression On Trastuzumab
Spector N. et al; March 2008; Clinical Breast Cancer; 8(S3); S94-9
Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group
Mackey JR. et al; January 2008; Current Oncology; 15(1); 24-35
Bevacizumab for Advanced Breast Cancer
Traina TA. et al; AprIL 2007; Hematology/Oncology Clinics of North America; 21(2); 303-319
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Smith I. et al; January 6, 2007; Lancet; 369(9555); 29-36
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer CE. et al; December 28, 2006; NEJM; 355(26); 2733-43
Management of HER2-Positive Breast Cancer
Winer EP. et al; ASCO 2006 Educational Book
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu H. et al; February 23, 2006; NEJM; 354(8); 809-20
Herceptin and the Heart -- A Molecular Modifier of Cardiac Failure
Chien KR. et al; February 23, 2006; NEJM; 354(8); 789-90
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart MJ. et al; October 20 2005; NEJM; 353(16); 1659-72
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
EH Romond et al, NEJM. Oct 20 2005; 353(16):1673-84
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel CL. et al; February 1, 2002; JCO; 20(3); 719-26
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Slamon DJ. et al; March 15, 2001; NEJM; 344(11); 783-92
Site Search
Advanced Search
Sign-up for Our E-Newsletter
Email Address
*
Help Us Grow!
Learn more about contributing to our website.